MAPK7 and melanoma: In this study, we not only provide a global phosphoproteomic profiling of CIBM, but also demonstrate that targeting BMK1 impairs the drug resistance and BMK1 inhibitor–XMD8-92 might have therapeutic potential for the treatment of melanoma.